摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-N-(1-((3,5-bis(trifluoromethyl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)-5-chloro-2-hydroxybenzamide

中文名称
——
中文别名
——
英文名称
(S)-N-(1-((3,5-bis(trifluoromethyl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)-5-chloro-2-hydroxybenzamide
英文别名
(S)-5-Chloro-2-hydroxy-N-(2-phenyl-1-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl)-ethyl)benzamide;N-[(2S)-1-[3,5-bis(trifluoromethyl)anilino]-1-oxo-3-phenylpropan-2-yl]-5-chloro-2-hydroxybenzamide
(S)-N-(1-((3,5-bis(trifluoromethyl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)-5-chloro-2-hydroxybenzamide化学式
CAS
——
化学式
C24H17ClF6N2O3
mdl
——
分子量
530.854
InChiKey
BIGRHWQTMOSHML-IBGZPJMESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.7
  • 重原子数:
    36
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    78.4
  • 氢给体数:
    3
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Inhibitors against the activation of ap-1 and nfat
    申请人:Muto Susumu
    公开号:US20060100257A1
    公开(公告)日:2006-05-11
    A medicament inhibiting the activation of AP-1 which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
    一种药物,抑制AP-1的激活,其活性成分为以下通式(I)所表示的化合物或其药学上可接受的盐、水合物或溶剂化物中所选的一种,其中X代表连接基,其主链中的原子数为2至5(该连接基可以被取代),A代表氢原子或乙酰基,E代表芳基或取代的杂芳基,环Z代表芳烃,除了由式—O-A所表示的基团外,可能还有一个或多个取代基,其中A具有上述定义的相同含义,由式—X-E所表示的基团中,X和E的每一个具有上述定义的相同含义,或者是一个杂芳烃,可能还有一个或多个取代基,其中A具有上述定义的相同含义,由式—X-E所表示的基团中,X和E的每一个具有上述定义的相同含义。
  • Medicament for treatment of diabetes
    申请人:Muto Susumu
    公开号:US20060111409A1
    公开(公告)日:2006-05-25
    A medicament for preventive and/or therapeutic treatment of diabetes or complications of diabetes which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O— A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
    一种用于预防和/或治疗糖尿病或糖尿病并发症的药物,其活性成分为以下通式(I)所表示的化合物或其药学上可接受的盐、水合物或溶剂化物之一: 其中,X代表主链中原子数为2到5的连接基(该连接基可以被取代),A代表氢原子或乙酰基,E代表可以被取代的芳基或杂环芳基,环Z代表可以具有一个或多个取代基的芳基,除了由公式—O—A所表示的基团外,该芳基可以具有公式—X-E所表示的基团,其中每个X和E的含义与上述定义相同,或者可以具有一个或多个取代基的杂环芳基,除了由公式—O—A所表示的基团外,该杂环芳基可以具有公式—X-E所表示的基团,其中每个X和E的含义与上述定义相同。
  • Antiallergic
    申请人:Muto Susumu
    公开号:US20060122243A1
    公开(公告)日:2006-06-08
    A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
    一种用于预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物,其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分,其中X代表主链中原子数为2到5的连接基(该连接基可以被取代),A代表氢原子或乙酰基,E代表可以被取代的芳基或杂环芳基,环Z代表可以具有一个或多个取代基的芳烃,除了由公式-O-A所表示的基团外,该芳烃还可以具有公式—X-E所表示的基团,其中每个X和E具有上述定义的相同含义,或者该环可以具有一个或多个取代基,除了由公式—O-A所表示的基团外,该环还可以具有公式—X-E所表示的基团,其中A具有上述定义的相同含义,X和E分别具有上述定义的相同含义。
  • Immunity-related protein kinase inhibitors
    申请人:Muto Susumu
    公开号:US20060019958A1
    公开(公告)日:2006-01-26
    A medicament having an inhibitory activity against IKK-β and/or MEKK-1 or other protein kinases structurally similar thereto, which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
    一种药物具有对IKK-β和/或MEKK-1或其他结构相似的蛋白激酶的抑制活性,其包括以下通式(I)所表示的化合物或其药学上可接受的盐,以及其水合物和溶剂化物作为活性成分的物质:其中,X表示连接主链中原子数为2至5的连接基(该连接基可以被取代),A表示氢原子或乙酰基,E表示可以被取代的芳基或取代的杂环芳基,环Z表示可以具有一个或多个取代基的芳烃,除了由式-O-A表示的基团外,该芳烃还可以具有式-X-E所表示的基团,其中每个X和E的含义与上述定义相同,或者是可以具有一个或多个取代基的杂环芳烃,除了由式-O-A表示的基团外,该杂环芳烃还可以具有式-X-E所表示的基团,其中每个X和E的含义与上述定义相同。
  • ANTIALLERGIC AGENTS
    申请人:Muto Susumu
    公开号:US20080090779A1
    公开(公告)日:2008-04-17
    A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
    一种预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物,其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分,其中X表示连接基,其主链中原子数为2至5(该连接基可以被取代),A表示氢原子或乙酰基,E表示芳基或取代的杂芳基,环Z表示苯环,除了由公式-O-A表示的基团,该苯环还可以具有一个或多个取代基团,其中A的含义与上述定义相同,而由公式-X-E表示的基团中,每个X和E的含义也与上述定义相同,或者是一个杂环,除了由公式-O-A表示的基团,该杂环还可以具有一个或多个取代基团,其中A的含义与上述定义相同,而由公式-X-E表示的基团中,每个X和E的含义也与上述定义相同。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物